Novelix Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 200695, "name": "Novelix Pharma.", "stock_name": "Novelix Pharma.", "full_name": "Novelix Pharmaceuticals Ltd", "name_url": "stocks-analysis/novelix-pharma", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "55.00", "chg": 0.03, "chgp": "0.05%", "dir": 1, "prev_price": "54.97", "mcapval": "112.00 Cr", "mcap": "Micro Cap", "scripcode": 536565, "symbol": "", "ind_name": "Retailing", "ind_code": 4, "indexname": "", "isin": "INE314I01036", "curr_date": "Mar 05", "curr_time": "", "bse_nse_vol": "3.3 k", "exc_status": "Active", "traded_date": "Mar 05, 2026", "traded_date_str": "2026 03 05", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/novelix-pharma-200695-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Novelix Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-hold-3869064", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/NovelixPharmace_mojoScore_3869064.png", "date": "2026-03-04 10:10:02", "description": "Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Novelix Pharmaceuticals Ltd Falls 2.26%: Key Valuation and Quality Shifts Shape Weekly Trend", "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-ltd-falls-226-key-valuation-and-quality-shifts-shape-weekly-trend-3863215", "imagepath": "", "date": "2026-03-01 13:00:05", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>16 Feb:</strong> Quality grade upgraded to average; valuation shifts from very expensive to expensive</p>\n <p><strong>17 Feb:</strong> Stock declines 2.56% despite Sensex gains</p>\n <p><strong>18 Feb:</strong> Strong rebound with 4.59% gain on heavy volume</p>\n <p><strong>19 Feb:</strong> Market correction impacts stock, down 1.95%</p>\n <p><strong>20 Feb:</strong> Week closes lower at Rs.61.04, down 3.05% on the day</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.62.45</div></div..." }, { "title": "Novelix Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/novelix-pharmaceuticals-ltd-is-rated-hold-3849418", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NovelixPharmace_mojoScore_3849418.png", "date": "2026-02-21 10:10:05", "description": "Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Novelix Pharmaceuticals Ltd Valuation Shift Signals Price Attractiveness Change", "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-ltd-valuation-shift-signals-price-attractiveness-change-3841337", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NovelixPharmace_valuationdot_3841337.png", "date": "2026-02-16 08:00:32", "description": "Novelix Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting evolving investor perceptions amid mixed financial metrics and sector comparisons. This article analyses the recent changes in key valuation ratios, their implications for price attractiveness, and how Novelix stacks up against its peers in the retailing sector." }, { "title": "Novelix Pharmaceuticals Ltd Quality Grade Upgrade Signals Mixed Business Fundamentals", "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-ltd-quality-grade-upgrade-signals-mixed-business-fundamentals-3841310", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NovelixPharmace_qualitydot_3841310.png", "date": "2026-02-16 08:00:18", "description": "Novelix Pharmaceuticals Ltd has seen its quality grade upgraded from below average to average, reflecting a nuanced shift in its business fundamentals. While the company demonstrates impressive sales growth and a clean debt profile, key profitability metrics such as ROCE and ROE remain subdued, indicating areas of concern for investors seeking consistent returns." }, { "title": "Novelix Pharmaceuticals Declines 2.04% Despite Strong Quarterly Growth: 3 Key Factors Behind the Week’s Moves", "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-declines-204-despite-strong-quarterly-growth-3-key-factors-behind-the-weeks-moves-3841095", "imagepath": "", "date": "2026-02-15 14:00:05", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Feb 9:</strong> Stock opens at Rs.62.56, declines 1.87% amid broad market gains</p>\n <p><strong>Feb 10:</strong> Modest recovery with 0.67% gain to Rs.62.98</p>\n <p><strong>Feb 12:</strong> Sharp fall of 2.06% to Rs.61.29 on weak market sentiment</p>\n <p><strong>Feb 13:</strong> Strong quarterly results announced; stock rebounds 1.89% to Rs.62.45</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.63.75</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div ..." }, { "title": "Are Novelix Pharmaceuticals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-novelix-pharmaceuticals-ltd-latest-results-good-or-bad-3838098", "imagepath": "", "date": "2026-02-13 19:47:42", "description": "Novelix Pharmaceuticals Ltd's latest financial results indicate a significant operational turnaround, with Q3 FY26 marking a return to profitability after a prolonged period of losses. The company reported net sales of ₹48.40 crores, the highest quarterly revenue in its history, and a net profit of ₹1.00 crore. This performance contrasts sharply with the losses recorded in previous fiscal years, particularly in FY22, where the company faced substantial declines in both sales and profitability.\n\nHowever, while the results show a positive trend, the operating profit margin of 2.71% remains modest, suggesting challenges in achieving sustainable profitability. The company's five-year average Return on Equity (ROE) stands at a low 0.74%, highlighting ongoing concerns about capital efficiency and the ability to generate meaningful returns for shareholders. Additionally, the absence of institutional investor parti..." }, { "title": "Novelix Pharmaceuticals Reports Very Positive Quarterly Financial Performance Amid Strong Revenue Growth", "link": "https://www.marketsmojo.com/news/stocks-in-action/novelix-pharmaceuticals-reports-very-positive-quarterly-financial-performance-amid-strong-revenue-growth-3837373", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NovelixPharmace_fintrenddot_3837373.png", "date": "2026-02-13 11:00:08", "description": "Novelix Pharmaceuticals Ltd has delivered its strongest quarterly financial performance to date in the December 2025 quarter, with record-breaking sales and profit metrics signalling a significant turnaround. Despite a mixed short-term stock return relative to the Sensex, the company’s financial trend has shifted from positive to very positive, reflecting robust operational execution and margin expansion in a challenging retailing sector environment." }, { "title": "Novelix Pharmaceuticals Q3 FY26: Stellar Turnaround Masks Underlying Fragility", "link": "https://www.marketsmojo.com/news/result-analysis/novelix-pharmaceuticals-q3-fy26-stellar-turnaround-masks-underlying-fragility-3837603", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NovelixPharmace_quaterlyResult_3837603.png", "date": "2026-02-13 09:20:12", "description": "Novelix Pharmaceuticals Limited has delivered its strongest quarterly performance in years during Q3 FY26, posting net sales of ₹48.40 crores and net profit of ₹1.00 crores—the highest figures in the company's recent operating history. Despite this impressive turnaround from consecutive quarters of losses, the micro-cap pharmaceutical retailer continues to trade at precarious valuations with a market capitalisation of just ₹108.00 crores and a concerning track record that raises serious questions about sustainability." } ], "total": 112, "sid": "200695", "stock_news_url": "https://www.marketsmojo.com/news/novelix-pharmaceuticals-200695" }, "announcements": [ { "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011", "datetime": "18-Feb-2026", "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mallela Venkataramna Reddy", "source": "BSE" }, { "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011", "datetime": "18-Feb-2026", "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Mallela Venkataramna Reddy", "source": "BSE" }, { "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011", "datetime": "18-Feb-2026", "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Vupparapalli Parvani", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Novelix Pharmaceuticals Ltd has declared <strong>3%</strong> dividend, ex-date: 16 Aug 12", "dt": "2012-08-16", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Novelix Pharmaceuticals Ltd has announced <strong>10:1</strong> stock split, ex-date: 04 Oct 10", "dt": "2010-10-04", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

Feb 9: Stock opens at Rs.62.56, declines 1.87% amid broad market gains

Feb 10: Modest recovery with 0.67% gain to Rs.62.98

Feb 12: Sharp fall of 2.06% to Rs.61.29 on weak market sentiment

Feb 13: Strong quarterly results announced; stock rebounds 1.89% to Rs.62.45

Week Open

Rs.63.75

Week Close

Read full news article

Are Novelix Pharmaceuticals Ltd latest results good or bad?

2026-02-13 19:47:42

Novelix Pharmaceuticals Ltd's latest financial results indicate a significant operational turnaround, with Q3 FY26 marking a return to profitability after a prolonged period of losses. The company reported net sales of ₹48.40 crores, the highest quarterly revenue in its history, and a net profit of ₹1.00 crore. This performance contrasts sharply with the losses recorded in previous fiscal years, particularly in FY22, where the company faced substantial declines in both sales and profitability. However, while the results show a positive trend, the operating profit margin of 2.71% remains modest, suggesting challenges in achieving sustainable profitability. The company's five-year average Return on Equity (ROE) stands at a low 0.74%, highlighting ongoing concerns about capital efficiency and the ability to generate meaningful returns for shareholders. Additionally, the absence of institutional investor parti...

Read full news article

Novelix Pharmaceuticals Reports Very Positive Quarterly Financial Performance Amid Strong Revenue Growth

2026-02-13 11:00:08

Novelix Pharmaceuticals Ltd has delivered its strongest quarterly financial performance to date in the December 2025 quarter, with record-breaking sales and profit metrics signalling a significant turnaround. Despite a mixed short-term stock return relative to the Sensex, the company’s financial trend has shifted from positive to very positive, reflecting robust operational execution and margin expansion in a challenging retailing sector environment.

Read full news article

Novelix Pharmaceuticals Q3 FY26: Stellar Turnaround Masks Underlying Fragility

2026-02-13 09:20:12

Novelix Pharmaceuticals Limited has delivered its strongest quarterly performance in years during Q3 FY26, posting net sales of ₹48.40 crores and net profit of ₹1.00 crores—the highest figures in the company's recent operating history. Despite this impressive turnaround from consecutive quarters of losses, the micro-cap pharmaceutical retailer continues to trade at precarious valuations with a market capitalisation of just ₹108.00 crores and a concerning track record that raises serious questions about sustainability.

Read full news article